ArticleJournal of gastrointestinal oncology2025
Metastatic pancreatic acinar cell carcinoma with
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Long-term survival with multidisciplinary treatment including local and systemic treatment for germline BRCA2-positive pancreatic acinar cell carcinoma.Clinical journal of gastroenterology · 2026Article
- Pathologic Complete Response to Modified FOLFIRINOX Enabling Conversion Surgery in Pancreatic Acinar Cell Carcinoma on Hemodialysis: A Case Report.Surgical case reports · 2026Article
- SFRT combined with immunotherapy for bulky hepatic metastasis from pancreatic acinar cell carcinoma: a case report.Frontiers in oncology · 2026Article
- Unexpected complete remission after recurrence in pancreatic cancer: a case report on comprehensive multimodal therapy.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic acinar cell carcinoma (PACC) is a rare subtype of pancreatic cancer, and its clinicopathological behavior is not fully understood because of its rarity. The excision of the tumor is the best treatment, but PACC patients often have distant metastasis at the time of first diagnosis and sometimes have relapse after surgery. Thus, appropriate anti-tumor agents need to be administered; however, there is still no standard chemotherapy regimen for PACC. We report a case of PACC in a patient with breast cancer susceptibility gene ( Case Description: A 67-year-old man was treated for breast cancer in 2016. In 2022, he experienced a continuous left back pain, and abdominal computed tomography (CT) revealed a 47-mm hypo-dense mass in the pancreatic tail and a 100-mm slightly enhanced mass in the liver at segment 8. He was diagnosed with PACC with liver metastasis by liver and pancreatic tumor biopsies. He was started on mFFX and, at the same time, we performed an analysis of the Conclusions: mFFX might be prioritized as the first-line chemotherapy for PACC patients, and an analysis of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.